Elauwit Connection Honored with Student Housing Business Innovator Award for Excellence in Connectivity Solutions
Columbia, South Carolina--(Newsfile Corp. - August 13, 2025) - Elauwit Connection Inc., a national managed services provider for the multifamily and student housing markets, is proud to announce the receipt of a prestigious Innovator Award from Student Housing Business magazine. Presented on April 10, 2025, the award recognizes the Company for its work in Best Off-Campus Bandwidth, Connectivity, and IoT Solutions. This accolade highlights Elauwit's deep expertise in retrofitting student housing properties with high-speed, reliable, and future-ready internet experiences.
The recognized project was a collaboration with Campus Advantage to upgrade the WiFi performance at The Spoke, a student housing property in Davis, California. Elauwit Connection designed and implemented a comprehensive fiber and network equipment upgrade, ensuring minimal disruption to residents. As a result, internet speeds surged from 30 Mbps to full Gigabit wired service, dramatically enhancing the overall resident experience.
Beth Pinder, Chief Operating Officer of Campus Advantage, stated in its press release about the award: "Immediate improvements were evident after switching to Elauwit. The upgrade transformed the resident experience from sluggish, dial-up-like speeds to a gamer's paradise, providing seamless, high-speed connectivity from sidewalk to sofa - encouraging lease renewals. Property marketing efforts promoting the new internet service provider led to residents swiftly dropping their third-party providers, resulting in better service and cost savings."
Taylor Jones, President and CTO of Elauwit, stated, "We were pleased to be able to offer students the WiFi experience they expect and deserve at a modern student living community. Even more, the immediate improvements have encouraged lease renewals and helped property marketing efforts, providing a win-win for both the property owner and the residents."
Elauwit's commitment to quality and reliability is underscored by its recent SOC 2 Type 2 Certification, a key milestone that affirms the company's ability to safeguard sensitive customer data with the highest standards of security and compliance. As a managed services provider, Elauwit empowers real estate to turn premium connectivity into a competitive advantage by prioritizing service quality, reliability, and revenue generation.
About Elauwit
Elauwit Connection is a national managed services provider delivering turnkey internet and connectivity solutions for multifamily and student housing communities. With a focus on service quality, reliability, and revenue generation, Elauwit enables real estate owners' delivery of premium connectivity as a competitive advantage.
For more information on Elauwit Connection, visit elauwit.com.
Contacts: Elauwit Connection Inc.Taylor Jones, President+1-704-558-3099sales-pr@elauwit.com
Investor Relations:
Matt Kreps, Darrow Associates +1-214-597-8200 mkreps@darrowir.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262375
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Soros, Appaloosa boost their Nvidia stake. They also bought this beaten-down stock, and it's rallying.
Soros Fund Management and Appaloosa Management both bought a whole lot more Nvidia Corp. stock during the second quarter, according to disclosures released Thursday, as the chip-maker occupies a spot dead-center in the artificial-intelligence boom. Both firms also bought more shares of embattled health-insurance giant UnitedHealth Group UNH over that period. Shares of that company jumped nearly 11% after hours, but they were down 46.3% on the year so far. Homeowners rush to refinance as mortgage-rate plunge opens window of opportunity My wife and I are in our 50s and have $11 million. We're not leaving it to our kids. Is that wrong? Soros Fund Management bought 932,539 shares of Nvidia NVDA, when combining puts and calls. The purchase marked a more than 1,600% increase, bringing the fund's total holdings to 990,292 shares. Appaloosa, meanwhile, bought 1.45 million shares of Nvidia, representing a 483.33% increase that brought the fund's total holdings to 1.75 million shares. Shares of Nvidia edged down 0.1% after hours on Thursday, but are up 35.5% so far this year. Appaloosa snapped up around 2.28 million shares of UnitedHealth representing a 1,300% increase in the fund's holdings in the stock. That brought Appaloosa's total holdings to 2.45 million shares. Soros bought 28,900 more shares of UnitedHealth during the quarter. Soros also bought new shares of Microsoft Corp. MSFT and Tesla Inc. TSLA — two other 'Magnificent Seven' stocks. It also added to its stake in Nike Inc. NKE. You could receive up to $7,500 from the AT&T settlement. Here's how class-action suits work. I'm a senior who barely survives on $1,300 a month. No way could I live on $1,000.
Yahoo
24 minutes ago
- Yahoo
Insiders Snap Up These 2 Stocks on the Dip — Here's Why They Draw Plaudits from Goldman Sachs
Every investor looks for signs that a stock might be worth the leap. While no single indicator guarantees success, some signals stand out as especially powerful when they appear together. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. One of the most reliable is insider buying. These are high-level executives and directors who have an intimate understanding of their company's operations, prospects, and challenges. They tend to put their own money on the line only when they believe the stock's future value will be higher. Better yet, their trades must be disclosed publicly, giving everyday investors a chance to watch and follow their moves. Another time-tested signal is the 'buy low, sell high' principle, spotting beaten-down stocks that have been oversold and may be poised for recovery. Price declines can sometimes signal trouble, but they can also reflect market overreactions, offering attractive entry points for those willing to look past the noise. The picture gets even stronger when this combination is validated by a heavyweight endorsement from Wall Street. A Buy rating from a firm like Goldman Sachs is more than an opinion – it's typically backed by deep research, robust industry modeling, and high-conviction guidance to clients. Such endorsements can boost investor confidence and help catalyze momentum. Against this backdrop, we've used the TipRanks database to pinpoint two stocks where all three forces align: insiders are buying, valuations look attractive after recent pullbacks, and Goldman Sachs is flashing a green light. When these signals converge, it's a setup that few investors can afford to ignore. Shift4 Payments (FOUR) We'll start our look at insider buying with Shift4 Payments, a payment processing company based in Pennsylvania that traces its roots back to 1999, when a teenage Jared Isaacman launched it from his parents' basement. His mission was to fill an 'efficiency niche' in payment processing by reducing the time and cost for merchants to get up and running. Today, the company sports a market cap approaching $8 billion and generates more than $3 billion in annual revenue. Over the years, Shift4 has expanded well beyond its early merchant focus. Its payment processing solutions now cater to customers across a wide range of industries, marketed as simple, safe, scalable, and smart – and tailored to individual client needs. Complementing these services, Shift4 offers point-of-sale systems, contactless commerce, and mobile payment capabilities. With offices across North America and Europe, the company supports over 100 payment methods in more than 150 currencies worldwide. That global reach got another boost on July 3, when Shift4 completed its $2.5 billion acquisition of Global Blue, a specialty payments and tech platform focused on international transactions, including tax-free shopping and currency conversion. The deal, priced at $7.50 per share, further strengthens Shift4's ability to serve cross-border clients. Such moves have helped the company build an impressive footprint: more than 200,000 customers, 500-plus technology integrations, and over 5 billion annual transactions totaling more than $260 billion. Yet, despite this strong operational base, the stock is down 14% year-to-date. The most recent spate of losses came after the August 5 earnings release for 2Q25. In that release, Shift4 showed quarterly revenues of $966.2 million, a figure that was up nearly 17% year over year but missed the forecast by just over $12 million. At the bottom line, the company's non-GAAP EPS of $1.10 also missed the forecast, coming in 10 cents per share lower than had been expected. Following the post-earnings pullback, founder and chairman Jared Isaacman moved quickly to buy the dip, scooping up 196,426 Shift4 shares between August 8 and August 11 for nearly $16.27 million, a move that signals strong confidence in the company's long-term prospects. That conviction appears to be shared on Wall Street, with Goldman Sachs analyst Will Nance viewing Shift4 as a potential growth story. 'We view FOUR as one of the top growth stories in our coverage and are constructive on the company's unique approach to M&A that has resulted in FOUR maintaining high levels of growth without incurring outsized customer acquisition costs. We expect this M&A strategy to continue, both in existing markets and increasingly in international markets. On that note, we believe that the Global Blue deal represents a solid addition to the company's customer acquisition funnel in Europe, and expect that FOUR has the potential to exceed its top line revenue synergy targets as it targets the low end of the Global Blue customer base, a group that historically relies on bank and legacy payment processors,' Nance opined. 'Importantly,' the analyst added, 'we believe FOUR can achieve these targets without any major enterprise wins, which we think is a common point of misunderstanding in the market, as some investors perceived the deal as FOUR looking to compete head to head with modern enterprise processors such as Adyen.' Quantifying this stance, Nance rates FOUR shares as a Buy, with a $104 price target that implies a ~17% upside for the coming year. (To watch Nance's track record, click here) Overall, Shift4's stock holds a Strong Buy consensus rating, based on 22 analyst reviews that include 17 Buys against 5 Holds. The shares are priced at $89.11, and their $107.75 average price target indicates room for a ~21% gain on the one-year horizon. (See FOUR stock forecast) Vertex Pharmaceuticals (VRTX) The next stock that has the combination of strong insider buys, a share price on the dip, and a bullish nod from Goldman Sachs is Vertex Pharmaceuticals. This company is a biotech researcher, with both a pipeline of drug candidates under development and a portfolio of approved medications on the market. That combination is something of a 'Holy Grail' for biotechs – and Vertex has reaped the rewards. The company was founded in 1989 and has since built itself into a $100 billion player in the field. Vertex's portfolio currently includes seven approved medications, and the company generated revenues of $11 billion last year and nearly $10 billion in 2023, with the bulk of that revenue coming from product sales. Vertex's product portfolio includes Trikafta, its largest revenue generator, which is a treatment for cystic fibrosis, and Kalydeco, another cystic fibrosis treatment, which was approved in 2012 and is Vertex's first approved drug. The company's most recently approved drugs are Casgevy, a treatment for sickle cell disease, approved in 2023; Alyftrek, a CF treatment for patients over age 6, approved in 2024; and Journavx, a non-opioid pain treatment approved in January of this year. The company's commercialized medications provided the bulk of its $2.96 billion in total quarterly revenue in 2Q25, the last period reported; of that total, $2.55 billion came from sales of Trikafta. Vertex's strong revenue totals support its research pipeline, under which the company continues to develop treatments for a wide range of conditions, including kidney disease, severe pain, beta thalassemia, and diabetes, as well as additional treatments for cystic fibrosis and sickle cell disease. The latest news about the company came from that development program, specifically as it relates to VX-993, a treatment for acute pain that was the subject of a recently completed Phase 2 clinical trial. On August 4, the same day that the company released its 2Q25 results, Vertex also announced that VX-993 failed to meet the primary endpoints of the study and will not be developed further as an acute pain monotherapy. The stock price has dropped sharply since that day and has not recovered; it is still down by 17%. That drop has not gone unnoticed in the C-suite. On August 6, two top insiders made substantial purchases: President and CEO Reshma Kewalramani bought 10,000 shares for nearly $3.9 million, and board member Bruce Sachs acquired 5,000 shares for $1.95 million. Goldman Sachs analyst Salween Richter shares that conviction, pointing to the company's expanding lineup of commercial products and the strength of several clinical-stage candidates. 'We recommend owning VRTX on continued commercial execution as demonstrated by the recent launches of Alyftrek in cystic fibrosis, noting a majority of treated patients are switch patients, and Journavx in acute pain, ahead of a 2H inflection, where we acknowledge access/reimbursement progress (inclusive of two of the three largest PBMs – the last is expected by YE); and potential emergence of a third commercial lever in povetacicept, where an interim analysis of the Ph3 RAINIER trial in IgA nephropathy (IgAN) could support an accelerated approval filing in 1H26, with expansion into other autoimmune renal diseases and cytopenias,' Richter wrote. Richter goes on to rate VRTX stock as a Buy and sets a $624 price target that indicates room for an upside of ~60% by this time next year. (To watch Richter's track record, click here) Overall, shares in Vertex hold a Moderate Buy consensus rating, based on 27 recent analyst reviews that split to 16 Buys and 11 Holds. The stock is priced at $390.30, and its average price target, now at $491.78, suggests a one-year upside potential of 26%. (See VRTX stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Warren Buffett's Berkshire Hathaway Earns $25 Every Second Just From Coca-Cola Stock Dividends Alone
Berkshire Hathaway (BRK.B) (BRK.A), led by legendary investor Warren Buffett, continues to demonstrate the compounding power of long-term value investing through its massive holding in Coca-Cola (KO). In 2025, the company's stake of approximately 400 million shares will generate an estimated $816 million in dividend income, thanks to Coca-Cola's projected annual dividend of $2.04 per share. This means that every single second of the year, Berkshire Hathaway will collect nearly $26 just from Coca-Cola dividends — a staggering flow of passive income from one stock alone. Breaking Down the Numbers At an annual payout of $816 million, Berkshire's Coca-Cola dividends break down as follows: Daily income: ~$2.23 million Hourly income: ~$93,150 Per minute: ~$1,552 Per second: ~$25.87 These figures underscore how a significant, long-held equity stake in a reliable dividend-paying company can provide enormous, consistent income — without requiring any active trading or asset sales. Don't Miss: 💎Don't Let That Cash Sit Idle, Secure These Top HYSA Interest Rates Before They Drop! 🚪Door Closing Soon: Lock in High-Value Rates for Your Savings Now! Why Coca-Cola Matters in Buffett's Portfolio Buffett began investing in Coca-Cola in the late 1980s, and over the decades it has become one of Berkshire's most iconic and rewarding investments. Coca-Cola's global brand presence, strong cash generation, and consistent dividend growth make it a model example of the type of business Buffett prefers: high-quality companies with enduring competitive advantages and shareholder-friendly capital allocation. The company's 2025 dividend payout is expected to remain at $0.51 per share quarterly, totaling $2.04 annually. This marks another year in Coca-Cola's long history of dependable distributions, providing Berkshire with a reliable cash stream that can be redeployed elsewhere within the conglomerate. Reinvesting, Not Distributing While Coca-Cola pays dividends, Berkshire Hathaway does not. Buffett has long argued that he can create more value by reinvesting capital within Berkshire than by returning it directly to shareholders. As a result, the billions in dividends received — like the $816 million this year from Coca-Cola — are typically used to fund acquisitions, buybacks, or support other holdings, further reinforcing Berkshire's internal compounding engine. Coca-Cola's payouts exemplify Buffett's preferred way to harvest cash flow: through stakes in mature, cash-rich businesses that return profits to shareholders without requiring operational control. Don't Miss: 🔥 Hot Rate Alert! Act Fast to Secure High Yields for Your Savings! 🚨 Today's High Rates May Not Be Available Tomorrow! Lock In Your HYSA Rate Today! Bigger Picture: Dividends Across the Portfolio Although Coca-Cola is a standout, it represents just one piece of Berkshire's broader dividend machine. In total, the company is expected to earn around $4.4 billion in dividends in 2025 from its publicly traded equity holdings. Other major contributors include Chevron (CVX), Bank of America (BAC), American Express (AXP), and Kraft Heinz (KHC). Still, Coca-Cola's role as a cornerstone holding illustrates the long-term payoff of patience and discipline in equity investing. With every passing second, Buffett's conviction in this timeless brand continues to compound — literally. On the date of publication, Caleb Naysmith did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
